Sharechat Logo

NZ Pharmaceuticals gets $49.6 mln cash injection as Archer Capital takes over

Monday 11th April 2016

Text too small?

New Zealand Pharmaceuticals, which manufactures specialty chemicals, has got a $49.6 million injection from its new controlling shareholder, Australian private equity firm Archer Capital. 

Last week local private equity firm Direct Capital completed the sale of its 51 percent stake in Palmerston North-based NZP for an undisclosed sum to Archer, saying it had been "very successful" for its investors. While the price wasn't disclosed,  Australian newspapers had previously reported it as being in the realm of $200 million.

Since Direct Capital first invested in 2005, the pharmaceutical products maker has invested in research and development capability, including the acquisition of Dextra Laboratories in the UK, and manufacturing facilities to expand its capacity. 

Documents lodged with the Companies Office show NZP issued 6.9 million of new shares at $7 apiece on March 31, lifting the total to 36.3 million and valuing the company at $254 million. Archer entities own about 73 percent of NZP's new holding company, Elviti Holdings, with senior management including chief executive Andy Lewis and directors Richard Garland and Barry Old. 

Archer's focus for NZP is on organic growth based on "robust underlying demand drivers together with new product R&D," the Australian firm's website said. 

Last year, the Australian private equity firm bought a group of training organisations under the umbrella of Aspire2 Group. 

NZP is the world's second-biggest manufacturer of cholic acid, a key ingredient for liver treatments, and the bulk of the firm's revenue is derived from export markets.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: Blue-chip stocks Meridian, A2 lead market lower
NZ dollar rises on Brexit hopes, rate cut reassessment
Three not failing, just needs a new owner - MediaWorks CEO
Major investors back new CBL class action targeting directors
Rip Curl purchase a done deal on Kathmandu proxies alone
Comvita chair Neil Craig eyes the exit once he finds a new CEO
Mercury raises guidance on increased storage, high spot prices
Eroad reports strong 3Q sales growth, eyes ASX listing
MediaWorks puts TV business on the block
NZ dollar benefits as preliminary Brexit deal improves risk appetite

IRG See IRG research reports